KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Total Debt: 2013-2025

Historic Total Debt for Travere Therapeutics (TVTX) over the last 5 years, with Jun 2025 value amounting to $68.8 million.

  • Travere Therapeutics' Total Debt was N/A to $68.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $68.8 million, marking a year-over-year change of. This contributed to the annual value of $68.7 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Travere Therapeutics reported Total Debt of $68.8 million as of Q2 2025, which was up 0.12% from $68.8 million recorded in Q1 2025.
  • Travere Therapeutics' 5-year Total Debt high stood at $68.8 million for Q2 2025, and its period low was $6.9 million during Q1 2023.
  • For the 3-year period, Travere Therapeutics' Total Debt averaged around $48.1 million, with its median value being $68.6 million (2024).
  • Data for Travere Therapeutics' Total Debt shows a maximum YoY crashed of 57.47% (in 2021) over the last 5 years.
  • Travere Therapeutics' Total Debt (Quarterly) stood at $7.4 million in 2021, then dropped by 5.41% to $7.0 million in 2022, then declined by 5.48% to $6.9 million in 2023, then reached $68.7 million in 2024, then reached $68.8 million in 2025.
  • Its Total Debt stands at $68.8 million for Q2 2025, versus $68.8 million for Q1 2025 and $68.7 million for Q4 2024.